BNTX stock news · BioNTech SE – ADR
Get alerts for BNTX
Follow BioNTech SE – ADR (BNTX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BNTXSyndax Pharmaceuticals, BioNTech, Seagate, and other major stocks dropped in value before the market opened on Tuesday.
NeutralThe article says BioNTech updated readers on a cancer-treatment trial but gives no trial result. It does not show a change in the company's prospects.
Invivyd is moving quickly to ask the FDA to approve its COVID-19 antibody.
NeutralThe report compares BioNTech’s vaccine alone with Invivyd’s antibody and the combined treatment. The combination showed fewer short-term side effects and higher antibody levels, but the story reports no new agreement or change in BioNTech’s sales.
Invivyd is getting ready to ask the FDA to quickly approve its COVID-19 antibody treatment.
NeutralBioNTech's Comirnaty vaccine was tested alone and with Invivyd's candidate. The report gives no news about a change to BioNTech's own business outlook.
Robinhood might jump about 23%. Check out 10 expert predictions for Tuesday.
Bad for BNTXBioNTech SE had its price target cut from $128 to $105 and the analyst downgraded the stock, indicating weaker analyst views.
Shares of BioNTech decline following the cancellation of the BNT122-01 clinical trial.
Bad for BNTXBioNTech SE's shares dropped 6.94% following the announcement of the termination of its Phase 2 clinical trial for autogene cevumeran, which was intended for patients with resected colorectal cancer.
After-hours trading sees Moderna shares retreat following a substantial 177% surge in cancer vaccine performance, with Merck, Pfizer, and BioNTech also gaining attention among mRNA stocks.
Bad for BNTXBioNTech's stock dipped after hours following a significant intraday gain, reflecting market reactions to mRNA cancer therapy developments.
What is Driving the Surge in BioNTech's Stock on Wednesday?
NeutralBioNTech's stock is surging due to investor reactions to promising clinical data from its individualized mRNA cancer therapy, which shows significant improvements in patient outcomes. This news is further bolstered by positive topline results from Merck and Moderna's similar therapies, enhancing the market's confidence in BioNTech's approach.